MYO18B

Across TCGA pan-cancer cohorts, MYO18B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYO18B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MYO18B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO18B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and KICH are the cancer types where MYO18B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.139	0.604	<.001	9	view →
UCEC	DFS	Median	All	0.771	0.621	.018	6	view →
KICH	DFS	Median	II,III,IV	0.102	0.775	.025	3	view →
SKCM	DFS	Median	II,III,IV	0.666	0.514	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYO18B–BLCA (OS)

Open the BLCA breakdown →